{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:54:51Z","timestamp":1791392091670,"version":"4.3.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"DOI":"10.1007\/s40744-026-00884-9","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:12:08Z","timestamp":1791389528000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Safety and Efficacy of Upadacitinib in Patients with Psoriatic Arthritis: 5-Year Results from the Phase\u00a03 SELECT-PsA\u00a01 Study"],"prefix":"10.1007","clinical-trial-number":[{"clinical-trial-number":"nct03104400","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Iain B.","family":"McInnes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Magrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsumasa","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Haaland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C.","family":"Coates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Lagunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Mancl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhumik","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Philips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"issue":"Suppl2","key":"884_CR1","doi-asserted-by":"publisher","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","volume":"64","author":"DD Gladman","year":"2005","unstructured":"Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(Suppl2):ii14\u20137. https:\/\/doi.org\/10.1136\/ard.2004.032482.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"884_CR2","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700\u201312. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217159.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"884_CR3","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/art.39573","volume":"68","author":"LC Coates","year":"2015","unstructured":"Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2015;68(5):1060\u201371. https:\/\/doi.org\/10.1002\/art.39573.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"884_CR4","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.semarthrit.2021.06.006","volume":"51","author":"D Poddubnyy","year":"2021","unstructured":"Poddubnyy D, Jadon DR, den Bosch FV, et al. Axial involvement in psoriatic arthritis: an update for rheumatologists. Semin Arthritis Rheum. 2021;51(4):880\u20137. https:\/\/doi.org\/10.1016\/j.semarthrit.2021.06.006.","journal-title":"Semin Arthritis Rheum"},{"key":"884_CR5","doi-asserted-by":"publisher","DOI":"10.1177\/1759720x20962623","volume":"12","author":"M Noviani","year":"2020","unstructured":"Noviani M, Feletar M, Nash P, et al. Choosing the right treatment for patients with psoriatic arthritis. Ther Adv Musculoskelet Dis. 2020;12:1759720X20962623. https:\/\/doi.org\/10.1177\/1759720x20962623.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"884_CR6","unstructured":"Rinvoq. Prescribing information, 2025. https:\/\/www.rxabbvie.com\/pdf\/rinvoq_pi.pdf. Accessed Sept 22, 2025."},{"issue":"1","key":"884_CR7","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40744-022-00499-w","volume":"10","author":"IB McInnes","year":"2023","unstructured":"McInnes IB, Kato K, Magrey M, et al. Efficacy and safety of upadacitinib in patients with psoriatic arthritis: 2-year results from the phase\u00a03 SELECT-PsA\u00a01 study. Rheumatol Ther. 2023;10(1):275\u201392. https:\/\/doi.org\/10.1007\/s40744-022-00499-w.","journal-title":"Rheumatol Ther"},{"key":"884_CR8","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1136\/annrheumdis-2023-eular.3116","volume":"82","author":"I Mcinnes","year":"2023","unstructured":"Mcinnes I, Kato K, Magrey M, et al. POS1541\u2005Long-term efficacy and safety of upadacitinib in patients with psoriatic arthritis: 3-year results from the phase\u00a03 SELECT-PsA\u00a01 study. Ann Rheum Dis. 2023;82:1137\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2023-eular.3116.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"884_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001838","volume":"7","author":"IB McInnes","year":"2021","unstructured":"McInnes IB, Kato K, Magrey M, et al. Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase\u00a03 SELECT-PsA\u00a01 study. RMD Open. 2021;7(3):e001838. https:\/\/doi.org\/10.1136\/rmdopen-2021-001838.","journal-title":"RMD Open"},{"issue":"13","key":"884_CR10","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1056\/nejmoa2022516","volume":"384","author":"IB McInnes","year":"2021","unstructured":"McInnes IB, Anderson JK, Magrey M, et al. Trial of upadacitinib and adalimumab for psoriatic arthritis. N Engl J Med. 2021;384(13):1227\u201339. https:\/\/doi.org\/10.1056\/nejmoa2022516.","journal-title":"N Engl J Med"},{"issue":"8","key":"884_CR11","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665\u201373. https:\/\/doi.org\/10.1002\/art.21972.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"884_CR12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/ard.2008.102053","volume":"69","author":"LC Coates","year":"2010","unstructured":"Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69(1):48. https:\/\/doi.org\/10.1136\/ard.2008.102053.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"884_CR13","doi-asserted-by":"publisher","first-page":"776","DOI":"10.26719\/emhj.22.074","volume":"28","author":"A Ylli","year":"2022","unstructured":"Ylli A, Burazeri G, Wu YY, et al. COVID-19 excess deaths in Eastern European countries associated with weaker regulation implementation and lower vaccination coverage. East Mediterr Health J. 2022;28(10):776\u201380. https:\/\/doi.org\/10.26719\/emhj.22.074.","journal-title":"East Mediterr Health J"},{"issue":"9","key":"884_CR14","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1136\/ard-2023-223916","volume":"82","author":"R Fleischmann","year":"2023","unstructured":"Fleischmann R, Curtis JR, Charles-Schoeman C, et al. Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase\u00a0III rheumatoid arthritis clinical programme. Ann Rheum Dis. 2023;82(9):1130\u201341. https:\/\/doi.org\/10.1136\/ard-2023-223916.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"884_CR15","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1136\/annrheumdis-2021-220418","volume":"80","author":"JA Sparks","year":"2021","unstructured":"Sparks JA, Wallace ZS, Seet AM, et al. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis. 2021;80(9):1137\u201346. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220418.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"884_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221146","volume":"82","author":"RF van Vollenhoven","year":"2023","unstructured":"van Vollenhoven RF, Tas SW, Nurmohamed MT. Correspondence on \u201cAssociations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry.\u201d Ann Rheum Dis. 2023;82(7):e177. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221146.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"884_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-025-05420-9","volume":"29","author":"\u00c1 J\u00e1nosi","year":"2025","unstructured":"J\u00e1nosi \u00c1, B\u00f3dy B, Nagy R, et al. Tumour necrosis factor-alpha inhibitors decrease mortality in COVID-19: a systematic review and meta-analysis. Crit Care. 2025;29(1):232. https:\/\/doi.org\/10.1186\/s13054-025-05420-9.","journal-title":"Crit Care"},{"issue":"10","key":"884_CR18","doi-asserted-by":"publisher","first-page":"5215","DOI":"10.1007\/s12325-025-03328-y","volume":"42","author":"GR Burmester","year":"2025","unstructured":"Burmester GR, Deodhar A, Irvine AD, et al. Safety profile of upadacitinib: descriptive analysis in over 27,000 patient-years across rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, atopic dermatitis, and inflammatory bowel disease. Adv Ther. 2025;42(10):5215\u2013371. https:\/\/doi.org\/10.1007\/s12325-025-03328-y.","journal-title":"Adv Ther"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00884-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-026-00884-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00884-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:12:09Z","timestamp":1791389529000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-026-00884-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":18,"alternative-id":["884"],"URL":"https:\/\/doi.org\/10.1007\/s40744-026-00884-9","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"17 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Financial arrangements of the authors with companies whose products may be related to the present manuscript are listed, as declared by the authors. Iain B. McInnes: Research grants and honoraria from AbbVie, Bristol Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, Sanofi Regeneron, and UCB. Koji Kato: Employee of AbbVie and may hold stock or options. Marina Magrey: Received research grants from Amgen, AbbVie, and UCB, and has received consulting fees from UCB, Novartis, Eli Lilly, Pfizer, and Janssen. Joseph F. Merola: Consultant and\/or investigator for Merck, Bristol Myers Squibb, AbbVie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Celgene, Sanofi, Regeneron, Arena, Sun Pharma, Biogen, Pfizer, EMD Serono, Avotres, and Leo Pharma. Mitsumasa Kishimoto: Consulting fees and\/or honoraria from AbbVie, Amgen, Asahi-Kasei Pharma, AstraZeneca, Ayumi Pharma, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Kyowa Kirin, Novartis, Tanabe-Mitsubishi, Taisho Pharma, and UCB. Derek Haaland: Advisory board\/speaker bureau or similar committee: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Novartis, Pfizer, Roche, Sanofi Genzyme, Takeda; Funded Grant or Clinical Trials: AbbVie, Adiga Life Sciences, Amgen, Bristol Myers Squibb, Can-Fite Biopharma, Celgene, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, Regeneron, Sanofi Genzyme, UCB; Honoraria or other fees: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, Roche, Sanofi Genzyme, Takeda, UCB; Not a part of: he has not received payment from a commercial organization (gifts or \u201cin kind\u201d compensation); does not hold a patent for a product referred to in the CME\/CPD program, or marketed by a commercial organization; he does not hold investments in a pharmaceutical organization, medical devices company or communications firm. Laura Coates: Received grants\/research support from AbbVie, Amgen, Janssen, and UCB; worked as a paid consultant for AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Enlivex, Janssen, MoonLake, Novartis, Pfizer, Takeda, and UCB; and has been paid as a speaker for AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. Ivan Lagunes: Employee of AbbVie and may hold stock or options. Yanxi Liu: Employee of AbbVie and may hold stock or options. Erin Mancl: Employee of AbbVie and may hold stock or options. Bhumikh Parikh: Employee of AbbVie and may hold stock or options. Charles Philips: Former employee of AbbVie and may hold AbbVie stock or options.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SELECT-PsA\u00a01 was conducted in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, applicable regulations governing clinical trial conduct, and the Declaration of Helsinki 1964 and its later amendments. As per Good Clinical Practice (GCP), the trial protocols were approved by an independent ethics committee (IEC)\/institutional review board (IRB) at each site. All patients provided written informed consent.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}